PMID- 32742488
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231002
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 11
IP  - 18
DP  - 2020
TI  - Abnormal spindle-like microcephaly-associated protein (ASPM) contributes to the 
      progression of Lung Squamous Cell Carcinoma (LSCC) by regulating CDK4.
PG  - 5413-5423
LID - 10.7150/jca.39760 [doi]
AB  - Lung cancer is a type of malignant tumor with high morbidity and mortality. Due 
      to its complicated etiology and clinical manifestations, no significant 
      therapeutic advance has been made. Lung squamous cell carcinoma (LSCC) is the 
      most common type of lung cancer. To combat this disease, novel therapeutic 
      targets are badly requirement. ASPM (Abnormal spindle-like 
      microcephaly-associated protein) is involved in multiple cellular or 
      developmental processes, such as neurogenesis and brain growth. ASPM is also 
      reported widely expressed in multiple tumor tissues and involved in the 
      development and progression of several cancers including lung cancer. However, 
      the potential role on ASPM on LSCC is still unclear. In this study, we reported 
      that ASPM was related to the poor prognosis of patients with lung squamous cell 
      carcinoma. Our results further showed that ASPM depletion dramatically inhibited 
      the proliferation of LSCC cells, consistent with the obviously decreased of 
      cyclin D1(CCND1) and cyclin dependent kinases 4 (CDK4) expression. In vivo assays 
      further confirmed ASPM ablation markedly blocked tumor growth in vivo compared 
      with control. In addition, a co-expression was found between ASPM and CDK4 in 
      human tumor tissues. Taken together, our data provides strong evidence that ASPM 
      promotes lung squamous cell carcinoma proliferation in vitro and in vivo, and 
      indicates its potential role as a LSCC therapeutic target.
CI  - (c) The author(s).
FAU - Yuan, Ya-Jing
AU  - Yuan YJ
AD  - Department of Anesthesia, Tianjin medical university cancer institute & hospital, 
      National clinical research center for cancer, Key laboratory of cancer prevention 
      and therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, 
      China.
FAU - Sun, Yao
AU  - Sun Y
AD  - Department of Radiation Oncology, Tianjin medical university cancer institute & 
      hospital, National clinical research center for cancer, Key laboratory of Cancer 
      Prevention and Therapy, Tianjin's clinical research center for cancer, Tianjin, 
      300060, China.
FAU - Gao, Rong
AU  - Gao R
AD  - Department of Pathology, Gansu Medical College, Pingliang City, Gansu Province, 
      744000, China.
FAU - Yin, Zhen-Zhen
AU  - Yin ZZ
AD  - Department of Radiation Oncology, Tianjin medical university cancer institute & 
      hospital, National clinical research center for cancer, Key laboratory of Cancer 
      Prevention and Therapy, Tianjin's clinical research center for cancer, Tianjin, 
      300060, China.
FAU - Yuan, Zhi-Yong
AU  - Yuan ZY
AD  - Department of Radiation Oncology, Tianjin medical university cancer institute & 
      hospital, National clinical research center for cancer, Key laboratory of Cancer 
      Prevention and Therapy, Tianjin's clinical research center for cancer, Tianjin, 
      300060, China.
FAU - Xu, Li-Ming
AU  - Xu LM
AD  - Department of Radiation Oncology, Tianjin medical university cancer institute & 
      hospital, National clinical research center for cancer, Key laboratory of Cancer 
      Prevention and Therapy, Tianjin's clinical research center for cancer, Tianjin, 
      300060, China.
AD  - Department of Radiation Oncology, Tianjin Medical University Cancer Hospital 
      airport hospital, Tianjin, 300308, China.
LA  - eng
PT  - Journal Article
DEP - 20200711
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
EIN - J Cancer. 2023 Sep 6;14(15):2845-2847. PMID: 37781081
PMC - PMC7391212
OTO - NOTNLM
OT  - ASPM
OT  - CDK4
OT  - Lung squamous cell carcinoma
OT  - Proliferation
OT  - Therapeutic target
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2020/08/04 06:00
MHDA- 2020/08/04 06:01
PMCR- 2020/01/01
CRDT- 2020/08/04 06:00
PHST- 2019/08/29 00:00 [received]
PHST- 2020/06/29 00:00 [accepted]
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2020/08/04 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - jcav11p5413 [pii]
AID - 10.7150/jca.39760 [doi]
PST - epublish
SO  - J Cancer. 2020 Jul 11;11(18):5413-5423. doi: 10.7150/jca.39760. eCollection 2020.